lunes, 21 de agosto de 2017

Childhood Soft Tissue Sarcoma Treatment (PDQ®)—Health Professional Version - National Cancer Institute

Childhood Soft Tissue Sarcoma Treatment (PDQ®)—Health Professional Version - National Cancer Institute

National Cancer Institute

Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version


Changes to This Summary (08/09/2017)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Added text to state that germline mutations or deletions of the SMARCB1(INI1) gene are associated with an increased risk of developing extrarenal rhabdoid tumors (cited Eaton et al. as reference 11).
Added text about the results of a review of 30 Italian patients with nonrhabdomyosarcomatous soft tissue sarcoma at visceral sites, including survival rates and unfavorable prognostic factors (cited Ferrari et al. as reference 61 and level of evidence 3iiB).
Added text to state that the current open trial (ARST1321 [NCT02180867]) uses the Fédération Nationale des Centres de Lutte Contre Le Cancer system to assign histological grade.
Added text to state that in a randomized study of 182 previously treated adult patients with recurrent liposarcoma, leiomyosarcoma, synovial sarcoma, and other sarcomas, patients with nonadipocytic tumors who were treated with regorafenib had significant improvements in progression-free survival when compared with patients who were treated with placebo (cited Mir et al. as reference 40).
Revised text to state that there are very limited data to support the use of trabectedin in pediatric patients (cited Baruchel et al. as reference 15).
The Dermatofibrosarcoma protuberans subsection was extensively revised.
Added Osborne et al. as reference 167.
Added text to state that a report of eight cases of liver angiosarcoma in children highlighted the misuse of the term hemangioendothelioma and the importance of early diagnosis and treatment of these tumors (cited Grassia et al. as reference 248).
Added text about the NCT01532687 trial as a treatment option under clinical evaluation for angiosarcoma of the soft tissue.
Added Stacchiotti et al. as reference 258.
Added text to state that one 13-year-old boy and one 14-year-old girl with multiply recurrent synovial sarcoma and lung metastases had responses to pazopanib for 14 and 15 months, respectively (cited Casanova et al. as reference 7 and level of evidence 3iiDi).
Added Treatment Options Under Clinical Evaluation as a new subsection for progressive/recurrent childhood soft tissue sarcoma.
This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.
  • Updated: August 9, 2017

No hay comentarios:

Publicar un comentario